AI Article Synopsis
- Nogo-A is a protein that inhibits nerve growth in the central nervous system, and its removal in mice doesn't significantly enhance nerve regeneration, indicating it may have additional roles.
- Targeted studies revealed that Nogo-A can be phosphorylated at Tyr-694 by Src-family tyrosine kinases, which are crucial for nervous system functions.
- This phosphorylation doesn't vary with the development of specific nerve cells (oligodendrocytes) and could be influenced by certain external signals, adding complexity to the understanding of Nogo-A's functions.
Article Abstract
Nogo-A is a neurite outgrowth inhibitor protein associated with myelin in the central nervous system. Unexpectedly, targeted disruption of Nogo-A in mice results in little or no improvement of axonal regeneration, suggesting that Nogo-A has other functions and/or receives complex regulations to exert its inhibitory functions. Here, we have found that Nogo-A becomes phosphorylated at Tyr-694 in the N-terminal region. The phosphorylation is mediated co-operatively by Src-family tyrosine kinases, which play many important roles in the nervous system. Levels of tyrosine phosphorylation of Nogo-A seem to be irrelevant to developmental stages of oligodendrocytes, and might be regulated by specific extracellular stimuli. Identification of tyrosine phosphorylation of Nogo-A will introduce an additional level of complexity into Nogo-A functions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2006.09.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial.
Lancet Neurol
January 2025
Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.
Background: Spinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute cervical traumatic spinal cord injury.
View Article and Find Full Text PDFOverexpression of Nogo-A changes nerve growth factor signaling dynamics in PC12 cells.
Cell Signal
December 2024
Research Service, Edward Hines Jr. Veterans Administration Hospital, Hines, IL, USA; Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
The nerve growth factor (NGF) receptor TrkA is a tightly regulated receptor tyrosine kinase that activates neuronal signaling pathways promoting cell survival in addition to axonal and dendritic outgrowth. Previously, we showed that NGF and TrkA signaling is altered in neuron-like PC12 cells that overexpress Nogo-A, a protein known to influence axonal outgrowth and dendritic arborization associated with neuronal plasticity. In the present report, we provide evidence for changes in NGF-mediated receptor-level and downstream signaling that occur in cells overexpressing Nogo-A.
View Article and Find Full Text PDFValidation of Peripheral Neuromodulation Mechanisms of Icariin in Knee Osteoarthritis-Related Chronic Pain.
J Cell Mol Med
December 2024
Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fuzhou, Fujian, China.
Knee osteoarthritis (KOA) is a chronic degenerative joint disease-causing chronic pain and disability. Neuromodulation of subchondral bone affects KOA-related pain and involves dorsal root ganglion (DRG). Our previous studies have demonstrated efficacy of icariin (ICA) in treating KOA, but neuromodulation mechanisms in peripheral nerves associated with the treatment of chronic pain in KOA remain unclear.
View Article and Find Full Text PDFIntrathecal administration of Anti-Nogo-A antibody in macaque monkeys: Pharmacokinetics, tissue penetration and target interaction.
Neurotherapeutics
November 2024
NovaGo Therapeutics AG, 8952 Zurich-Schlieren, Switzerland. Electronic address:
Article Synopsis
- Intrathecal drug administration is a promising method for delivering biologics to the central nervous system (CNS), but there is limited knowledge on how well intrathecally applied antibodies are tolerated and their pharmacokinetics.
- This study involved administering a human monoclonal antibody against Nogo-A to non-human primates, assessing toxicity, pharmacokinetics, and pharmacodynamics with no observed side effects, indicating good tolerability.
- Findings showed that the antibody was rapidly cleared from the cerebrospinal fluid but accumulated in the serum, effectively targeting Nogo-A in the CNS, which could enhance therapeutic strategies for CNS diseases.
Correction: An unexpected role of Nogo-A as regulator of tooth enamel formation.
Int J Oral Sci
November 2024
Orofacial Development and Regeneration, Institute of Oral Biology, University of Zürich, Zürich, Switzerland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!